Antibody drug discovery takes center stage at ESMO, Zymeworks outlines

Antibody drug discovery takes center stage at ESMO, Zymeworks outlines
Zymeworks targets ADC discovery

Zymeworks announced the upcoming presentations by two of its senior researchers at the ESMO Targeted Anticancer Therapies Congress in Paris from March 16 to 19.

Nina E. Weisser, Senior Director of Multispecific Antibody Therapeutics, and Raffaele Colombo, Associate Director of Medicinal Chemistry, will offer insights into the development of multispecific antibody therapies. Colombo will specifically present on the path to antibody drug conjugate (ADC) discovery, underscoring the company’s emphasis on innovative oncology solutions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.